Terms: = Prostate cancer AND ATIC, IMPCHASE, 471, ENSG00000138363, AICARFT, P31939, PURH AND Treatment
47 results:
1. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
2. Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
Joshy G; Khalatbari-Soltani S; Soga K; Butow P; Laidsaar-Powell R; Koczwara B; Rankin NM; Brown S; Weber M; Mazariego C; Grogan P; Stubbs J; Thottunkal S; Canfell K; Blyth FM; Banks E
BMC Cancer; 2023 Sep; 23(1):774. PubMed ID: 37700229
[TBL] [Abstract] [Full Text] [Related]
3. Low risk is low risk, regardless of race or ethnicity: Outcomes of prostate cancer active surveillance and factors associated with reclassification in a racially diverse cohort.
Labagnara K; Zhu D; Loloi J; Shreck E; Abeshouse M; Watts KL; Sankin A; Aboumohamed AA; Kovac E
Urol Oncol; 2023 Apr; 41(4):204.e7-204.e15. PubMed ID: 36740489
[TBL] [Abstract] [Full Text] [Related]
4. Follow-up strategy and survival for five common cancers: A meta-analysis.
Galjart B; Höppener DJ; Aerts JGJV; Bangma CH; Verhoef C; Grünhagen DJ
Eur J Cancer; 2022 Oct; 174():185-199. PubMed ID: 36037595
[TBL] [Abstract] [Full Text] [Related]
5. Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With cancer.
Taparra K; Qu V; Pollom E
JAMA Netw Open; 2022 Aug; 5(8):e2226327. PubMed ID: 35960520
[TBL] [Abstract] [Full Text] [Related]
6. Overall Survival Update for Patients with Metastatic Castration-resistant prostate cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Crabb SJ; Griffiths G; Dunkley D; Downs N; Ellis M; Radford M; Light M; Northey J; Whitehead A; Wilding S; Birtle AJ; Khoo V; Jones RJ
Eur Urol; 2022 Nov; 82(5):512-515. PubMed ID: 35688662
[TBL] [Abstract] [Full Text] [Related]
7. The Relationship Between PSA and Total Testosterone Levels in Men With prostate cancer.
Flores JM; Bernie HL; Miranda E; Nascimento B; Schofield E; Benfante N; Carlsson S; Mulhall JP
J Sex Med; 2022 Mar; 19(3):471-478. PubMed ID: 35135736
[TBL] [Abstract] [Full Text] [Related]
8. Illness representations, coping and anxiety among men with localized prostate cancer over an 18-months period: A parallel vs. level-contrast mediation approach.
Otto I; Hilger C; Magheli A; Stadler G; Kendel F
Psychooncology; 2022 Feb; 31(2):227-237. PubMed ID: 34467601
[TBL] [Abstract] [Full Text] [Related]
9. Evolving role of
Satapathy S; Sood A; Das CK; Mittal BR
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L
J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255
[TBL] [Abstract] [Full Text] [Related]
11. prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
[TBL] [Abstract] [Full Text] [Related]
12. Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.
Voskuilen CS; Seiler R; Rink M; Poyet C; Noon AP; Roghmann F; Necchi A; Aziz A; Lavollé A; Young MJ; Marks P; Saba K; van Rhijn BWG; Fransen van de Putte EE; Ablat J; Black PC; Sosnowski R; Dobruch J; Kumar P; Jallad S; Catto JWF; Xylinas E; Hendricksen K;
Eur Urol Focus; 2020 Nov; 6(6):1226-1232. PubMed ID: 30559065
[TBL] [Abstract] [Full Text] [Related]
13. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
[TBL] [Abstract] [Full Text] [Related]
14. Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.
Jung EJ; Chung KH; Kim CW
BMB Rep; 2017 Sep; 50(9):466-471. PubMed ID: 28803608
[TBL] [Abstract] [Full Text] [Related]
15. Multiparametric Magnetic Resonance Imaging of the prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.
Fedorov A; Vangel MG; Tempany CM; Fennessy FM
Invest Radiol; 2017 Sep; 52(9):538-546. PubMed ID: 28463931
[TBL] [Abstract] [Full Text] [Related]
16. Anatomical Retzius-space preservation is associated with lower incidence of postoperative inguinal hernia development after robot-assisted radical prostatectomy.
Chang KD; Abdel Raheem A; Santok GDR; Kim LHC; Lum TGH; Lee SH; Ham WS; Choi YD; Rha KH
Hernia; 2017 Aug; 21(4):555-561. PubMed ID: 28160111
[TBL] [Abstract] [Full Text] [Related]
17. Psychometric testing of the Norwegian version of the Expanded prostate cancer Index Composite 26-item version (EPIC-26).
Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
[TBL] [Abstract] [Full Text] [Related]
18. Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome.
Hatzichristodoulou G; Wagenpfeil S; Weirich G; Autenrieth M; Maurer T; Thalgott M; Horn T; Heck M; Herkommer K; Gschwend JE; Kübler H
World J Urol; 2016 Feb; 34(2):229-36. PubMed ID: 26100945
[TBL] [Abstract] [Full Text] [Related]
19. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Fokidis HB; Yieng Chin M; Ho VW; Adomat HH; Soma KK; Fazli L; Nip KM; Cox M; Krystal G; Zoubeidi A; Tomlinson Guns ES
J Steroid Biochem Mol Biol; 2015 Jun; 150():35-45. PubMed ID: 25797030
[TBL] [Abstract] [Full Text] [Related]
20. prostate cancer risk prediction based on complete prostate cancer family history.
Albright F; Stephenson RA; Agarwal N; Teerlink CC; Lowrance WT; Farnham JM; Albright LA
Prostate; 2015 Mar; 75(4):390-8. PubMed ID: 25408531
[TBL] [Abstract] [Full Text] [Related]
[Next]
